Skip to main content
Top
Published in: Globalization and Health 1/2011

Open Access 01-12-2011 | Debate

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

Authors: Suerie Moon, Elodie Jambert, Michelle Childs, Tido von Schoen-Angerer

Published in: Globalization and Health | Issue 1/2011

Login to get access

Abstract

Background

Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices systematically lower than in industrialized countries - has received widespread support from industry, policymakers, civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies, drug-resistant tuberculosis medicines, liposomal amphotericin B (for visceral leishmaniasis), and pneumococcal vaccines.

Discussion

We found several critical shortcomings to tiered pricing: it is inferior to competition for achieving the lowest sustainable prices; it often involves arbitrary divisions between markets and/or countries, which can lead to very high prices for middle-income markets; and it leaves a disproportionate amount of decision-making power in the hands of sellers vis-à-vis consumers. In many developing countries, resources are often stretched so tight that affordability can only be approached by selling medicines at or near the cost of production. Policies that "de-link" the financing of R&D from the price of medicines merit further attention, since they can reward innovation while exploiting robust competition in production to generate the lowest sustainable prices. However, in special cases - such as when market volumes are very small or multi-source production capacity is lacking - tiered pricing may offer the only practical option to meet short-term needs for access to a product. In such cases, steps should be taken to ensure affordability and availability in the longer-term.

Summary

To ensure access to medicines for populations in need, alternate strategies should be explored that harness the power of competition, avoid arbitrary market segmentation, and/or recognize government responsibilities. Competition should generally be the default option for achieving affordability, as it has proven superior to tiered pricing for reliably achieving the lowest sustainable prices.
Appendix
Available only for authorised users
Literature
4.
go back to reference Sukkar E: UK kick-starts differential pricing debate for developing world. Scrip World News. 2009, 28-29. Sukkar E: UK kick-starts differential pricing debate for developing world. Scrip World News. 2009, 28-29.
6.
go back to reference Mackay B: Summary report of Industry Government Forum on Access to Medicines (IGFAM). 2009, London: DFID Health Resources Center. Meeting report Mackay B: Summary report of Industry Government Forum on Access to Medicines (IGFAM). 2009, London: DFID Health Resources Center. Meeting report
9.
go back to reference Plahte J: Tiered pricing of vaccines: A win-win-win situation, not a subsidy. Lancet Infect Dis. 2005, 5: 58-63. 10.1016/S1473-3099(04)01255-1CrossRefPubMed Plahte J: Tiered pricing of vaccines: A win-win-win situation, not a subsidy. Lancet Infect Dis. 2005, 5: 58-63. 10.1016/S1473-3099(04)01255-1CrossRefPubMed
10.
go back to reference Ramsey FP: A contribution to the theory of taxation. Econ J. 1927, 37: 47-61. 10.2307/2222721.CrossRef Ramsey FP: A contribution to the theory of taxation. Econ J. 1927, 37: 47-61. 10.2307/2222721.CrossRef
11.
go back to reference WHO : The world drug situation. 1988, Geneva WHO : The world drug situation. 1988, Geneva
12.
go back to reference Xu K, Evans D, Kawabata K, Zeramdini R, Klavus J, Murray CJ: Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003, 362: 111-117. 10.1016/S0140-6736(03)13861-5CrossRefPubMed Xu K, Evans D, Kawabata K, Zeramdini R, Klavus J, Murray CJ: Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003, 362: 111-117. 10.1016/S0140-6736(03)13861-5CrossRefPubMed
13.
go back to reference WHO : Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). Public Health, Innovation and Intellectual Property Rights. 2006, Geneva WHO : Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). Public Health, Innovation and Intellectual Property Rights. 2006, Geneva
14.
15.
go back to reference Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R: Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010, 7: e1000333-CrossRefPubMedPubMedCentral Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R: Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010, 7: e1000333-CrossRefPubMedPubMedCentral
16.
go back to reference Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP: Global strategies to reduce the price of antiretroviral medicines. Evidence from transactional databases. Bull World Health Organ. 2009, 87: 520-528. 10.2471/BLT.08.058925CrossRefPubMedPubMedCentral Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP: Global strategies to reduce the price of antiretroviral medicines. Evidence from transactional databases. Bull World Health Organ. 2009, 87: 520-528. 10.2471/BLT.08.058925CrossRefPubMedPubMedCentral
17.
18.
go back to reference Frank RG, Salkever DS: Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy. 1997, 6: 75-90. 10.1162/105864097567039.CrossRef Frank RG, Salkever DS: Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy. 1997, 6: 75-90. 10.1162/105864097567039.CrossRef
19.
go back to reference Baker BK, Ombaka E: The danger of in-kind drug donations to the Global Fund. Lancet. 2009, 373: 1218-1221. 10.1016/S0140-6736(08)61487-7CrossRefPubMed Baker BK, Ombaka E: The danger of in-kind drug donations to the Global Fund. Lancet. 2009, 373: 1218-1221. 10.1016/S0140-6736(08)61487-7CrossRefPubMed
20.
go back to reference Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S: Intervening in global markets to improve access to HIV/AIDS treatment: An analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health. 2010, 6: 9-CrossRefPubMedPubMedCentral Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S: Intervening in global markets to improve access to HIV/AIDS treatment: An analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health. 2010, 6: 9-CrossRefPubMedPubMedCentral
21.
go back to reference WHO : Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. 2009, Geneva WHO : Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. 2009, Geneva
22.
go back to reference WHO : Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. 2009, Geneva WHO : Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. 2009, Geneva
25.
go back to reference Waning B, Diedrichsen E, Moon S: Market shift towards heat-stable lopinavir/ritonavir demonstrates the need for improved formulations for second-line treatment of HIV/AIDS in low- and middle-income countries. Poster Presentation, XVIII International AIDS Conference. 2010, Vienna Waning B, Diedrichsen E, Moon S: Market shift towards heat-stable lopinavir/ritonavir demonstrates the need for improved formulations for second-line treatment of HIV/AIDS in low- and middle-income countries. Poster Presentation, XVIII International AIDS Conference. 2010, Vienna
26.
go back to reference Carreyrou J: New regimen: Inside Abbott's tactics to protect AIDS drug. Wall St J. 2007 Carreyrou J: New regimen: Inside Abbott's tactics to protect AIDS drug. Wall St J. 2007
29.
go back to reference WHO : WHO and Novartis join forces to combat drug resistant malaria. 2001 WHO : WHO and Novartis join forces to combat drug resistant malaria. 2001
30.
go back to reference Moon S, Pérez Casas C, Kindermans J, de Smet M, von Schoen-Angerer T: Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med. 2009, 6: e1000106. 10.1371/journal.pmed.1000106CrossRefPubMedPubMedCentral Moon S, Pérez Casas C, Kindermans J, de Smet M, von Schoen-Angerer T: Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med. 2009, 6: e1000106. 10.1371/journal.pmed.1000106CrossRefPubMedPubMedCentral
32.
33.
go back to reference WHO : Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update. 2008, Geneva WHO : Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update. 2008, Geneva
34.
go back to reference WHO : Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. 2011, Geneva WHO : Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. 2011, Geneva
35.
go back to reference Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J: Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006, 43: 917-924.CrossRefPubMed Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J: Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006, 43: 917-924.CrossRefPubMed
36.
go back to reference GAVI Alliance : Advance Market Commitment for Pneumococcal Vaccines: Annual Report 12 June 2009-31 March 2010. 2010, Geneva GAVI Alliance : Advance Market Commitment for Pneumococcal Vaccines: Annual Report 12 June 2009-31 March 2010. 2010, Geneva
38.
go back to reference Jack A: GSK signs lifetime deal with Brazil for pneumococcal vaccine. Financ Times. 2009 Jack A: GSK signs lifetime deal with Brazil for pneumococcal vaccine. Financ Times. 2009
39.
go back to reference Wilson P: Giving developing countries the best shot: An overview of vaccine access and R&D. Oxfam International and MSF Campaign for Access to Essential Medicines. Geneva:. 2010 Wilson P: Giving developing countries the best shot: An overview of vaccine access and R&D. Oxfam International and MSF Campaign for Access to Essential Medicines. Geneva:. 2010
40.
go back to reference Yadav P: Differential pricing: The interface of economics and supply chains. 2009, Presented at DFID Industry-Government Forum on Access to Medicines., London Yadav P: Differential pricing: The interface of economics and supply chains. 2009, Presented at DFID Industry-Government Forum on Access to Medicines., London
42.
go back to reference Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet. 2009, 373: 240-249. 10.1016/S0140-6736(08)61762-6CrossRefPubMed Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet. 2009, 373: 240-249. 10.1016/S0140-6736(08)61762-6CrossRefPubMed
44.
go back to reference Wong EV: Inequality and pharmaceutical drug prices: An empirical exercise. Discussion Papers in Economics. Center for Economic Analysis, Department of Economics, University of Colorado, Boulder, CO. Working Paper 02-19. Wong EV: Inequality and pharmaceutical drug prices: An empirical exercise. Discussion Papers in Economics. Center for Economic Analysis, Department of Economics, University of Colorado, Boulder, CO. Working Paper 02-19.
45.
go back to reference Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K: Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand. AIDS. 2007, 21 (Suppl 4): S21-S29.CrossRefPubMed Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K: Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand. AIDS. 2007, 21 (Suppl 4): S21-S29.CrossRefPubMed
46.
go back to reference Lopert R, Lang DL, Hill SR, Henry DA: Differential pricing of drugs: A role for cost-effectiveness analysis?. Lancet. 2002, 359: 2105-2107. 10.1016/S0140-6736(02)08911-0CrossRefPubMed Lopert R, Lang DL, Hill SR, Henry DA: Differential pricing of drugs: A role for cost-effectiveness analysis?. Lancet. 2002, 359: 2105-2107. 10.1016/S0140-6736(02)08911-0CrossRefPubMed
47.
go back to reference Organisation for Economic Cooperation and Development (OECD) : Pharmaceutical Pricing Policies in a Global Market. OECD Health Policy Studies. 2008 Organisation for Economic Cooperation and Development (OECD) : Pharmaceutical Pricing Policies in a Global Market. OECD Health Policy Studies. 2008
48.
go back to reference 't Hoen E: The global politics of pharmaceutical monopoly power: Drug patents, access, innovation, and the application of the WTO Doha Declaration on TRIPS and public health. 2009, Diemen, the Netherlands: AMB Press 't Hoen E: The global politics of pharmaceutical monopoly power: Drug patents, access, innovation, and the application of the WTO Doha Declaration on TRIPS and public health. 2009, Diemen, the Netherlands: AMB Press
51.
go back to reference Finkelstein SN, Temin P: Reasonable Rx: Solving the Drug Price Crisis. Upper Saddle River, NJ: FT Press/Pearson Education. 2008 Finkelstein SN, Temin P: Reasonable Rx: Solving the Drug Price Crisis. Upper Saddle River, NJ: FT Press/Pearson Education. 2008
52.
go back to reference Bermudez J, 't Hoen E: The UNITAID Patent Pool Initiative: Bringing patents together for the common good. Open AIDS J. 2010, 4: 37-40. 10.2174/1874613601004020037CrossRefPubMedPubMedCentral Bermudez J, 't Hoen E: The UNITAID Patent Pool Initiative: Bringing patents together for the common good. Open AIDS J. 2010, 4: 37-40. 10.2174/1874613601004020037CrossRefPubMedPubMedCentral
53.
go back to reference Outterson K: Patent buy-outs for global disease innovations for low- and middle-income countries. Am J Law Med. 2006, 32: 159-173.PubMed Outterson K: Patent buy-outs for global disease innovations for low- and middle-income countries. Am J Law Med. 2006, 32: 159-173.PubMed
Metadata
Title
A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries
Authors
Suerie Moon
Elodie Jambert
Michelle Childs
Tido von Schoen-Angerer
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2011
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/1744-8603-7-39

Other articles of this Issue 1/2011

Globalization and Health 1/2011 Go to the issue